Fig. 2: Hematologic parameters and response rates in myelodysplastic syndromes (MDS) and aplastic anemia (AA) cases according to PNH positivity. | Leukemia

Fig. 2: Hematologic parameters and response rates in myelodysplastic syndromes (MDS) and aplastic anemia (AA) cases according to PNH positivity.

From: Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia

Fig. 2

A Median blood counts and LDH levels +SD in PNH+ (gray bars) and PNH− (white bars) MDS cases; p = 0.04 for Hb; p < 0.0001 for PLT and LDH. B Median blood counts and LDH levels ± SD in PNH+ (gray bars) and PNH− (white bars) AA cases; p < 0.0001 for PLT and LDH. Blood counts were collected at the time of PNH clone testing, hence the positive impact of transfusions on baseline hemoglobin and platelets cannot be excluded in transfusion-dependent patients. C Forest plot of relative risk for response to treatments in PNH+ and PNH− MDS cases. D Forest plot of relative risk for response to treatments in PNH+ and PNH− AA cases. Good outcome after HSCT was considered as 6 month persistent disease remission. Hb hemoglobin, ANC absolute neutrophil counts, PLT platelets, LDH lactate dehydrogenase, HSCT hematopoietic stem cell transplant, IST immunsuppressive therapy, AZA azacytidine, ORR overall response rate.

Back to article page